Vox Markets Logo

Today’s AIM Movers with Diurnal Group rising over 200% following grant of second US patent, featuring DNL, MTPH, OBT, GAN, I3E, IMTK

12:57, 10th January 2019
Abraham Darwyne
AIM Movers
TwitterFacebookLinkedIn

A round up of today’s AIM listed movers

Diurnal Group (DNL) FOLLOW rose over 230% to a high of 71p following the announcement it has been granted a second US patent for Chronocort, a drug in a key US market where it has already received two Orphan Drug Designations. The patent is for a method of treatment for adrenal dysfunction, delivering hydrocortisone in accordance with a circadian rhythm. The patent provides in-market protection until 2033, with potential for seven years of market exclusivity on approval from the FDA. The US market for the diseases the patent covers is estimated to be approximately $1 billion.

DNL price chart

Midatech Pharma (MTPH) FOLLOW rose 25% to 7.375p following the announcement of a funding from the Basque Regional Government for 1.5 million Euros for the company manufacturing facility in Bilbao Spain. It is to continue and accelerate the progress of MTD201 towards approval submission to the FDA and for the development of its Q-Sphere platform. The sustained release technology has the potential to drastically improve the manufacturing process and clinical characteristics of existing drugs.

MTPH price chart

Obtala (OBT) FOLLOW is up over 16% following the news it had completed a set of deals to narrow its focus to timber trading and production and reorganise its corporate structure. It disposed it’s agricultural business for $2.5m, and received a vote of confidence from intuitional investment players after securing an investment from 1798 Volantis Fund, managed by Lombard Odier Asset Management, as well as granting share options and a loan facility. 

OBT price chart

GAN FOLLOW is up 13% to 60p following the announcement it secured a long-term deal with FanDuel Group to be it’s platform for the deployment of Internet casino and account services for internet sports betting. The gaming B2B software supplier also entered into an agreement to have FDG license GAN’s US patent. The patented technology is proven to greatly enhance online engagement by US casino patrons and increase lifetime value realized online. 

GAN price chart

i3 Energy (I3E) FOLLOW is up 14% to 59.5p following news that the oil & gas company had signed a letter of intent with Dolphin Drilling for a multi-well drilling campaign this summer across the Liberator field and Serenity prospect. i3 also received indicative terms from Repson Sinopec UK for Liberator's use of their leased Bleo Holm FPSO, allowing i3 access to infrastructure without immense capital expenditure.

I3E price chart

Imaginatik (IMTK) FOLLOW is down 37% following the announcement that it entered into a conditional agreement to sell the business and assets of the company. It will sell its name, associated domains and trademarks and trading assets for $1.7 million payable on completion and up to a further $800,000 depending on certain conditions. CEO Angus Forrest said “"Whilst considerable progress has been made in improving the business, there is still more to do to ensure the business has a successful independent future.  The Board believes the offer received from Planbox Inc recognises the progress made and it is in the interests of all Imaginatik shareholders to approve the sale of the business."

IMTK price chart

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist